Health Robotics Announces SINOPHARM Deal

Last week we wrote about Health Robotics' expansion into the Australian market and their deal with Device Technologies Australia.

Today, the company announced an exclusive five-year strategic agreement with China National Pharmaceutical Foreign Trade Corporation (SINOPHARM Foreign Trade), which will distribute and support the company's CytoCare and i.v.STATION Robots.

SINOPHARM is a wholly owned People's Republic of China Government (PRC) company.

The arrangement is designed to enable SINOPHARM to safely, accurately and cost-effectively automate the preparation of hazardous and non-hazardous IV Admixtures in China, including Hong Kong and Macao.

"Health systems and government entities in China are determined to deliver the best health care and medication management to their people. The expansion of CytoCare and i.v.STATION into China will fulfill our Government's health care strategic direction and improve the provision of medical services in our country," stated Wu Jian Feng, General Manager of SINOPHARM Foreign Trade's Healthcare Division.

Werner Rainer, Health Robotics' CEO was excited to announce the deal. "This is the zenith of a great summer and an excellent year for Health Robotics. To add SINOPHARM, the largest medical device and drug distribution company in China to our other strategic partners is a dream come true for Health Robotics," he said.